Thank you, Erin.
Friday, for letter response conference last of complete the on we on a new know, discussed contents We Monday. oliceridine you application. call the As the received FDA our from letter drug
ahead. to disappointed I’d The analgesics highlighted set how now we IV accomplish and oliceridine approved, become us work an will steps will of believe four do investor So items that following business we the we important question oliceridine with the take advance like meeting questions CRL. need about today, comments once remain to currently We to the our what will our limited confident FDA. program, hospital. Obviously, the is addition to confidence. for we that rebuild in The by our focus the were resolve on distinct letter be addressable
plan. the Here’s
provide oliceridine. to have made organization expenses. but on to on have will prioritize runway, we work details one-third. reduce will how a to John difficult decision targeted smaller, First, reduce Today, impacts this cash workforce by about our our we we and a more
to and development, expertise items each plan. us have help help people clinical address can skills raised Trevena, we who need key we and retained FDA. manufacturing At our regulatory work the by and Second, necessary the of us through non-clinical in
In clinical focused deliver consultant experience area NDAs letters, what with have on external working and exactly with the Together, and well be that are information. to oliceridine addition, approve how agency. experts electrophysiology with efficiently cardiac regulator understanding who complete of as on seasoned to as we we companies with most the FDA needs working will and response in
finalize path we potential of a Institute spending for dependence. this or the Third, pause will early with work have investment TRVXXX NIDA on opioid for Abuse needed Drug forward better continue understanding and on of pause, National until we the treat the Despite pipeline our to to we’ll the oliceridine.
to for for for the options, we and modulators SXP treatment We TRVXXX acute which our won’t to of plans these will critical those instances, is advancing may non-narcotic continue evaluate potential chronic assets but own strategic expenditures pipeline be partnering pain, believe also can migraine in includes with some we We the cash oliceridine. on decision-making. we extra enable the weigh investments incur but our versus until delays information
Finally, to using we and capital on efficiently. committing lines stakeholders focused reducing managing risks, Trevena we that are are time all
and on with FDA value. Our plan investors a coming our reach are month goal pipeline is in to gives to confidence early path the agreement we that on oliceridine a building
the more of happen but incredible There’s won’t to amount as we scenes, coming to work behind learn an overnight. in All the are months. updating you of committed this we do
and of for the risk with We our anesthesiologists. to were positive ATHENA Annual physicians who from XXX of of for Dr. a pain option open-label hospital trial the help interactions meeting over support and highlights. at had will The at of Before Also a and John, we at possibility XX. Trevena. I turn and XX% pain a both experience American the experience announced it the included we and the elevated study we oliceridine moderate XX% over society October, I’d like pharmaceutical patients in In operational this the we October, his age BMIs investment acute of the Meeting to the the Dr. in of Board encouraged the of available asset with to Braunstein than be recent specialty and tremendous events, our patients about to patients’ appointment with mention XX were few number patients safety manage more Scott received future to has care. Braunstein excited opioid-related by severe space, adverse to in substantial over Directors. of insights presented having treatment improve
of Finally, clinical dependence TRVXXX for opioid of the presented support recently behavior. this in contemplates We this model at They’ve of of we’ve important rodent continued NIDA look as continuing NIDA to effects data beneficial TRVXXX evaluate a and TRVXXX showing forward Society as they evaluation dependence. for opioid for Neuroscience Meeting treatment need. to drug-seeking Annual collaboration the unmet
to I review John? our over the hand John will financials. to Now call
